Xencor (NASDAQ:XNCR) Stock Price Up 10.3% – What’s Next?

Xencor, Inc. (NASDAQ:XNCR)’s stock price shot up 10.3% on Monday . The stock traded as high as $13.92 and last traded at $13.9390. 351,163 shares traded hands during trading, a decline of 55% from the average daily volume of 775,809 shares. The stock had previously closed at $12.64.

Analysts Set New Price Targets

XNCR has been the subject of a number of research analyst reports. Zacks Research lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. boosted their price objective on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Barclays upped their price objective on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $24.50.

Xencor Trading Up 2.5%

The firm has a 50-day simple moving average of $12.18 and a two-hundred day simple moving average of $12.89. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -6.32 and a beta of 0.92.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The firm had revenue of $4.52 million for the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The firm’s quarterly revenue was down 86.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.66) earnings per share. On average, sell-side analysts forecast that Xencor, Inc. will post -3.84 earnings per share for the current year.

Institutional Trading of Xencor

A number of institutional investors have recently added to or reduced their stakes in XNCR. Tower Research Capital LLC TRC increased its stake in shares of Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 3,018 shares during the last quarter. E Fund Management Co. Ltd. acquired a new stake in shares of Xencor in the 2nd quarter valued at $79,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Xencor in the 4th quarter valued at $81,000. iSAM Funds UK Ltd bought a new stake in Xencor in the second quarter worth $122,000. Finally, Prelude Capital Management LLC bought a new stake in Xencor in the third quarter worth $139,000.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.